Clinical Trial Update: Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the safety, immunogenicity, and ex-vivo efficacy of two candidate malaria transmission-blocking vaccines (Pfs25-IMX313 and P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• Matrix-M adjuvant (Matrix-M)
• Pfs25-IMX313
• Pfs45/48

Snippet

Sponsor: University of Oxford | Conditions: Plasmodium Falciparum Malaria | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING